Bhavneesh Sharma, Manisha Sharma, Elliott Bondi, Brookdale University Hospital and Medical Center, Division of Pulmonary and Critical Care medicine, State University of New York, Brooklyn, New York 11212, United States
Mradul Kumar Daga, Gopal Krishan Sachdev, University of Delhi, Maulana Azad Medical College, Divisions of Pulmonary medicine and Gastroenterology, New Delhi 110002, India
Supported by a research grant from the University of Delhi, No. 52301/01 and Glaxo Smithkline Pharmaceuticals Limited and Dr. Reddy’s Laboratories Ltd, No. 9834512
Correspondence to: Bhavneesh Sharma, MD, Department of Internal Medicine, Brookdale University Hospital and Medical Center, State University of New York, Brooklyn, New York 11212, United States. firstname.lastname@example.org
Telephone: +1-718-2405000 Fax: +1-718-2406344
Received: 2007-01-17 Accepted: 2007-01-31
AIM: to study the effect of combined omeprazole(Ome) and domperidone(Dom) therapy on asthma symptoms and pulmonary function in asthmatics with gastroesophageal reflux.
METHODS: We selected 198 asthmatics with gastroesophageal reflux diagnosed by 24-h esophageal pH monitoring to receive ome 20 mg twice daily and dom 10 mg three times daily or placebo for 16 wk (1:1 double-blind randomization). Spirometry was done at baseline and after 16 wk of treatment. The primary outcome measures were: mean daily daytime and nighttime asthma symptom scores. Mean daily reflux symptom scores, albuterol use as rescue medication (number of puffs), daytime and nighttime peak expiratory flow rate (PEFR), postbronchodilator forced expiratory volume in 1 second (FEV1) and postbronchodilator forced vital capacity (FVC) were secondary outcome measures.
RESULTS: Comparison of mean change from baseline between antireflux therapy and placebo groups revealed significant reduction in daytime asthma symptom score (17.4% vs 8.9 %), nighttime asthma symptom score (19.6% vs 5.4%), reflux symptom score (8.7% vs 1.6%) and rescue medication use (23.2% vs 3.1%) after antireflux therapy compared to mean change in placebo group (p < 0.001). There was significant improvement in morning PEFR (7.9% vs 0.2%), evening PEFR (9.8% vs 0.5%), FEV1 (11.1% vs 3.78%) and FVC (9.3% vs 1.52%) in the antireflux therapy group compared to placebo on comparing the mean change from baseline after 16 wk (p < 0.01).
CONCLUSION: Combined therapy with ome and dom in adult asthmatics with gastroesophageal reflux may be beneficial by reducing asthma symptoms, rescuing medication use, and improving pulmonary function.
© 2007 The WJG Press. All rights reserved.
Key words: Asthma; reflux; Gastroesophageal reflux disease; antireflux therapy; prokinetic; omeprazole
Sharma B, Sharma M, Daga MK, Sachdev GK, Bondi E. Effect of omeprazole and domperidone on adult asthmatics with gastroesophageal reflux. World J Gastroenterol 2007; 13(11): 1706-1710
Gastroesophageal reflux disease (GERD) and asthma are two common diseases that afflict millions of people all over the world. The exact relationship between GERD and asthma has been a source of constant debate. GERD is reportedly the most common trigger in difficult-to-control asthma. Various mechanisms contributing to GERD exacerbating asthma include a vagus-mediated reflex, a local axonal reflex, heightened bronchial reactivity[4,5], and microaspiration[6,7]. GERD is more prevalent in asthmatics compared with control populations and asthmatics frequently associate GERD symptoms with their asthma symptoms. Previous studies have estimated the prevalence of GERD in adult asthmatics at between 34% and 80%[8-10]. Asthma symptoms also correlated with esophageal pH events on 24-h esophageal pH monitoring.
Previous studies on the effect of antireflux therapy on asthma have shown inconsistent results[12-24]. Most of these studies have been done in small groups of patients with different proton-pump inhibitors and were done for short durations of anti-reflux therapy. There is limited data on the use of prokinetic agents in asthmatics with GERD and so far, only one study has explored the effect of a combination of a proton pump inhibitor and a prokinetic agent in asthmatics with GERD. The present study was done to study the effect of combined therapy with omeprazole, a proton-pump inhibitor and domperidone, a prokinetic agent on asthma symptoms and pulmonary function in asthmatics with GERD.
MATERIALS AND METHODS
A total of 410 adult asthma patients attending the outpatient medicine
and pulmonary clinics of Lok Nayak Hospital, a tertiary teaching
hospital affiliated with Maulana Azad Medical College, University of
Delhi, India, were screened after obtaining informed consent. The study
was approved by the Institutional Review Board of the hospital. All
patients underwent 24-h esophageal pH monitoring to detect GERD. The
inclusion criteria of the study at screening included the following: (1)
> 18 years of age; (2) > 12% improvement in FEV1 (in litres) after
inhalation of 180 mg of albuterol; (3) mild-to-moderate persistent
asthma; (4) no exacerbations or significant change in asthma medications
during past weeks of screening; and (5) GERD as diagnosed by 24-hour
esophageal pH monitoring. GERD was defined as positive if the total time
for which pH was < 4 was > 4.5%. Exclusion criteria
included the following: (1) any unstable chronic medical condition; (2)
history of smoking in past or present; (3) history of any other lung
disease except asthma; and (4) use of antireflux medications including
antacids, histamine-2-receptor antagonists, proton pump inhibitors or
prokinetic agents. GERD was diagnosed in 247 asthmatics after 24-h
esophageal pH monitoring. Of 247 patients with GERD, 18 patients had
history of smoking, 10 patients had history of recent asthma
exacerbation, 8 patients were receiving omeprazole therapy, 5 patients
were receiving antacids and 2 patients withdrew the consent. After
screening, remaining 204 patients for selected for randomization, of
At initial screening (Figure 1), a detailed medical history, physical
examination and laboratory tests were done from July 4, 2001 to August
18, 2003 in all asthmatics with GERD who met the inclusion and exclusion
Statistical analysis was done using SPSS 12.0 (SPSS Inc, Chicago, Illinois, United States) statistical software. Comparison between baseline and post-treatment parameters within treatment groups was done using paired t test. Comparison of mean percentage change from baseline after 16 wk of therapy between two treatment groups was done using Fisher’s exact test. p values were two-sided and were considered significant at < 0.05.
At baseline (Table 1), the antireflux therapy and placebo groups were matched with no significant difference between various parameters like age, sex, body mass index, asthma symptoms, reflux symptoms, rescue medication use, FEV1 and FVC. There was no significant difference in medication compliance between antireflux therapy and placebo groups based on pill counts (95.2% ± 7.4% vs 96.7% ±6.3%, p = 0.87).
There was 17.4% reduction in the daytime asthma symptom score (p = 0.0002), 19.6% reduction in nighttime asthma symptom score (p = 0.0007) and 8.7% reduction in reflux symptom score after antireflux therapy compared to baseline (p = 0.0001). Antireflux therapy resulted in 23.2% reduction in rescue medication use (p = 0.0001), 7.9% improvement in morning PEFR (p = 0.005), 9.8% improvement in evening PEFR (p = 0.003), 11.1% improvement in FEV1 (L) (p = 0.001) and 9.3% improvement in FVC (L) compared to baseline (p = 0.002).
Comparison of mean change from baseline between antireflux therapy and placebo groups revealed significant reduction in daytime asthma symptom score (17.4% vs 8.94%, p = 0.0001), nighttime asthma symptom score (19.6% vs 5.4%, p = 0.0001), reflux symptom score (8.7% vs 1.6%, p = 0.0003) and rescue medication use (23.2% vs 3.08%, p = 0.0001) after antireflux therapy compared to mean change in placebo group. There was significant improvement in morning PEFR (7.9% vs 0.2%, p = 0.004), evening PEFR (9.8% vs 0.5%, p = 0.002), FEV1 in L (11.1% vs 3.78%, p = 0.0013) and FVC in L (9.3% vs 1.52%, p = 0.0023) in the antireflux therapy group compared to placebo on comparing the mean change from baseline after 16 wk. These results are demonstrated in table 1. Improvement in primary and secondary outcome measures was seen in all 99 patients treated with antireflux therapy.
Maintenance medication and adverse events
All patients were treated with one inhalation of salmetrol 50 mg and fluticasone propionate 250 mg taken two times everyday at 8:00 and 20:00 (Seretide; Glaxo Smithkline Pharmaceuticals Limited, Mumbai, India). There was no significant difference in the maintenance mediation dose between two treatment groups at baseline. There was no change in the maintenance medication during the treatment period in two treatment groups.
There was no significant difference in treatment-emergent adverse events between antireflux therapy and placebo groups over 16 wk of treatment (64% vs 60%, P = 0.7). The percentages of severe adverse events were similar in the two treatment groups (10% vs 8%, p = 0.4). The severe adverse events included myalgia (4%), aggression (3%), thrombocytopenia (1%), urticaria (1%) and Steven-Johnson syndrome (1%) in the antireflux therapy group.
This study shows a significant improvement in daytime and nocturnal
asthma symptoms, reflux symptoms, daytime and nighttime PEFR, FEV1
and FVC after omeprazole and domperidone therapy for 16 wk compared to
placebo. This is the second study in medical literature investigating
Results of past studies investigating the effect of proton-pump inhibitor therapy on asthma outcome have shown variable results. Some recent studies using different proton pump inhibitors in asthmatics include those by Calabrese et al using pantoprozole 80 mg daily in 34 asthmatics for 6 mo (25 patients had a complete recovery of esophagitis and reflux symptoms and 27 patients had normalization of FEV1), Kiljander et al using esomeprazole 40 mg twice daily for 16 wk in 350 asthmatics with GERD and nocturnal respiratory symptoms (significant improvement in morning and evening PEFR), Littner et al using lansoprozole 30 mg twice daily for 24 wk in 207 asthmatics with acid reflux symptoms (reduction in asthma exacerbations and improved asthma quality of life, but no improvement in asthma symptoms or pulmonary function), Gopal et al using ome 20 mg daily for 4 wk in 70 asthmatics with significant reflux (significant improvement in asthma symptom scores and pulmonary function), and Eryuksel et al using pantoprozale 40 mg daily for 3 mo in 28 asthmatics with laryngopharyngeal reflux as shown by indirect videolaryngoscopy (significant reduction in asthma and laryngopharyngeal sreflux symptoms). On reviewing the combined results of 12 studies examining medical therapy in 326 treated asthmatics with GERD in a meta-analysis, asthma symptoms improved in 69%, medication use was reduced in 62%, and evening PEFR rates improved in 26% of patients; however, pulmonary function did not improve. A recent Cochrane Database review examined 12 randomized controlled trials studying antireflux therapy in asthmatics and noted no overall improvement in asthma after GERD therapy. However, they concluded that subgroups of patients may benefit and pointed out the importance of examining predictors of asthma response.
The role of non-acid reflux in asthmatics who do not respond to proto-pump inhibitor therapy has been described. We speculate that a sub-group of asthmatics may have increased bronchial responsiveness on exposure to non-acid reflux including bile acids, bile salts and pancreatic enzymes. Combined therapy with a proton pump inhibitor and prokinetic agent may help asthmatics with gastroesophageal reflux by reducing acid as well as non-acid reflux. A new technique, esophageal impedance monitoring makes it possible to detect non-acid reflux and may provide future directions to exploring the relationship between non-acid reflux and asthma. A large on-going trial is exploring the prevalence of acid and non-acid GERD in moderate to severe asthma children aged 1-18 years referred for gastrointestinal evaluation.
We used dom, a prokinetic agent in addition to omeprazole to treat GERD in our study. Prokinetics have been shown to have a definite role in the treatment of gastroesophageal reflux disease. In short term treatment of gastro-esophageal reflux disease, cisapride (10 mg four times a day or 20 mg twice daily) has proved more effective than placebo and nearly as effective as H2 blockers in relieving symptoms and healing esophagitis. Cisapride (10 mg twice daily or 20 mg at bedtime) also prevents relapses in patients with mild esophagitis. Studies using metoclopramide also showed an improvement in reflux symptoms compared to placebo using metoclopramide 10 mg four times a d. Domperidone, the prokinetic agent used in our study, is a dopamine antagonist,which does not cross the blood–brain barrier and thus has a better safety profile, with no significant CNS side effects and only a minor incidence of gynecomastia and galactorrhea. Domperidone acts by increasing lower esophageal sphincter tone and by enhancing upper gastrointestinal separately, acting on one of the pathophysiological mechanisms of GERD. It antagonizes the inhibitory effect of dopamine, resulting in stimulation of gastric muscle contraction. This provides a mechanism for the gastrokinetic effect of domperidone. In a randomized, double-blind, controlled trial conducted in pediatric population, dom caused a significant reduction in vomiting compared to metoclopramide and placebo. A study comparing different maintenance therapies for reflux esophagitis has concluded that addition of prokinetic with antisecretory agent decreases relapse (relapse rate 20% with ome and only 11% with combination of ome and cisapride). However, Sekiguchi et al found that cisapride often actually exacerbated acid reflux in another study. The use of combination therapy with omeprazole and domperidone should be monitored closely in asthmatics.
In conclusion, our data suggests that combined therapy with ome and dom for 16 wk in asthmatics with GERD may be beneficial by reducing asthma symptoms and rescue medication use, and improving pulmonary function.
1 Richter JE. Gastroesophageal reflux disease and asthma:
the two are directly related. Am J Med 2000; 108 Suppl 4a:
2 Wright RA, Miller SA, Corsello BF. Acid-induced
esophagobronchial-cardiac reflexes in humans. Gastroenterology
3 Fischer A, McGregor GP, Saria A, Philippin B, Kummer W.
Induction of tachykinin gene and peptide expression in guinea
4 Vincent D, Cohen-Jonathan AM, Leport J, Merrouche M,
Geronimi A, Pradalier A, Soule JC. Gastro-oesophageal reflux
5 Cuttitta G, Cibella F, Visconti A, Scichilone N, Bellia V,
Bonsignore G. Spontaneous gastroesophageal reflux and airway
6 Tuchman DN, Boyle JT, Pack AI, Scwartz J, Kokonos M,
Spitzer AR, Cohen S. Comparison of airway responses following
7 Jack CI, Calverley PM, Donnelly RJ, Tran J, Russell G,
Hind CR, Evans CC. Simultaneous tracheal and oesophageal pH
8 Harding SM. GERD, airway disease, and the mechanisms of
interaction. In: Stein MR. Lung biology in health and
9 Nagel RA, Brown P, Perks WH, Wilson RS, Kerr GD.
Ambulatory pH monitoring of gastro-oesophageal reflux in “morning
10 Sontag SJ, O’Connell S, Khandelwal S, Miller T, Nemchausky
B, Schnell TG, Serlovsky R. Most asthmatics have
11 Harding SM, Guzzo MR, Richter JE. 24-h esophageal pH
asthmatics: respiratory symptom correlation with
Salomaa ER, Hietanen EK, Terho EO. Gastroesophageal reflux in
asthmatics: A double-blind, placebo-
13 Ford GA, Oliver PS, Prior JS, Butland RJ, Wilkinson SP.
Omeprazole in the treatment of asthmatics with nocturnal
14 Meier JH, McNally PR, Punja M, Freeman SR, Sudduth RH,
Stocker N, Perry M, Spaulding HS. Does omeprazole
Kronborg IJ, Yeomans ND, Robinson P. Adult asthma and gastro-oesophageal
reflux: the effects of
16 Levin TR, Sperling RM, McQuaid KR. Omeprazole improves peak
expiratory flow rate and quality of life in asthmatics
17 Boeree MJ, Peters FT, Postma DS, Kleibeuker JH. No effects
of high-dose omeprazole in patients with severe airway
18 Harmanci E, Entok E, Metintas M, Vardareli E, Elbek O.
Gastroesophageal reflux in the patients with asthma. Allergol
19 Jiang SP, Liang RY, Zeng ZY, Liu QL, Liang YK, Li JG.
Effects of antireflux treatment on bronchial hyper-responsiveness
20 Calabrese C, Fabbri A, Areni A, Scialpi C, Zahlane D, Di
Febo G. Asthma and gastroesophageal reflux disease: effect of
21 Kiljander TO, Harding SM, Field SK, Stein MR, Nelson HS,
Ekelund J, Illueca M, Beckman O, Sostek MB. Effects of
22 Littner MR, Leung FW, Ballard ED 2nd, Huang B, Samra
NK. Effects of 24 weeks of lansoprazole therapy on asthma
23 Gopal B, Singhal P, Gaur SN. Gastroesophageal reflux
disease in bronchial asthma and the response to omeprazole.
24 Eryuksel E, Dogan M, Golabi P, Sehitoglu MA, Celikel T.
Treatment of laryngopharyngeal reflux improves asthma
25 Field SK, Sutherland LR. Does medical antireflux therapy
improve asthma in asthmatics with gastroesophageal reflux? a
26 Jamieson JR, Stein HJ, DeMeester TR, Bonavina L, Schwizer W,
Hinder RA, Albertucci M. Ambulatory 24-h esophageal
27 Ayres JG, Campbell LM. A controlled assessment of an asthma
self-management plan involving a budesonide dose
28 Robinson DS, Campbell D, Barnes PJ. Addition of
leukotriene antagonists to therapy in chronic persistent asthma: a
29 Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O’Byrne
P, Barnes PJ, Ullman A. Effect of inhaled formoterol and
30 Harding SM, Richter JE, Guzzo MR, Schan CA, Alexander RW,
Bradley LA. Asthma and gastroesophageal reflux: acid
31 Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux
treatment for asthma in adults and children. Cochrane
32 Harding SM. Gastroesophageal reflux: a potential asthma trigger. Immunol Allergy Clin North Am 2005; 25: 131-148
33 Mehta DI. Importance of non-acid reflux in asthma in
34 Tytgat GN, Janssens J, Reynolds JC, Wienbeck M. Update on
the pathophysiology and management of gastro-
35 Blum AL, Adami B, Bouzo MH, Brandstatter G, Fumagalli I,
Galmiche JP, Hebbeln H, Hentschel E, Huttemann W, SChutz
36 McCallum RW, Fink SM, Winnan GR, Avella J, Callachan C.
Metoclopramide in gastroesophageal reflux disease:
37 Takahashi T, Kurosawa S, Wiley JW, Owyang C. Mechanism for
the gastrokinetic action of domperidone. In vitro studies
38 De Loore I, Van Ravensteyn H, Ameryckx L. Domperidone drops
in the symptomatic treatment of chronic paediatric
39 Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena
M, Savarino V, Di Mario F, Battaglia G, Mela GS, Pilotto A. A
40 Sekiguchi T, Nishioka T, Matsuzaki T, Sugiyama M, Kusano M,
Horikoshi T, Toki M, Ohwada T, Kobayashi S.
S- Editor Wang J L- Editor Rampone B E-Editor Chin GJ